Chronic Lymphocytic Leukemia Complications and Management

Major Complications

CLL patients face three primary categories of complications: autoimmune cytopenias, severe infections due to immune deficiency, and disease transformation, each requiring distinct management strategies 1, 2

The European Society for Medical Oncology recommends first-line treatment with corticosteroids for autoimmune cytopenias, including AIHA and immune thrombocytopenia, which are effective in most patients 1, 2
Second-line options for steroid-refractory cases include rituximab administration before considering splenectomy, monoclonal antibodies, and thrombopoietin analogs in selected cases, with splenectomy remaining a reasonable treatment choice for non-responders 1, 2, 3

The American Society of Clinical Oncology notes that most CLL patients develop severe immune defects during disease progression, making infections the most common complication, but prophylactic intravenous immunoglobulin is not recommended routinely as it does not improve overall survival 1, 2
Selective prophylaxis indications include patients with severe hypogammaglobulinemia and repeated infections, who may receive IV immunoglobulin, as well as antibiotic, antiviral, or antifungal prophylaxis for patients with recurrent infections 1, 2, 3
Vaccination recommendations include pneumococcal vaccination in early-stage CLL and seasonal influenza vaccination 3

The National Comprehensive Cancer Network states that transformation to aggressive lymphoma, Hodgkin's lymphoma, or B-cell prolymphocytic leukemia occurs in 2-15% of patients and carries a very poor prognosis, except for Hodgkin transformation 1, 2
Treatment by transformation type includes rituximab plus hyper-CVAD for Richter's syndrome, conventional chemotherapy against Hodgkin's disease, and FCR regimen for B-cell prolymphocytic leukemia 1, 2, 3

The International Society of Geriatric Oncology notes that CLL patients have a two- to sevenfold increased risk of developing secondary malignancies, predominantly solid cancers but also myelodysplastic syndromes or acute myeloblastic leukemia, requiring life-long surveillance 3

The European Hematology Association recommends key monitoring, including special attention to the appearance of autoimmune cytopenias during follow-up 3